Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 Trial

Abstract

Using CFS as our main end point, we did not find an advantage for either ICT or HD radiation boost in LAACC. Nevertheless, the results of the most treatment-intense arm B should prompt the design of further intensification studies.

Randomized Phase 2 Trial of S1 and Oxaliplatin-Based Chemoradiotherapy With or Without Induction Chemotherapy for Esophageal Cancer

“…Our results suggest that the 3-step approach may not provide additional benefit to CCRT in patients with locally advanced esophageal squamous cell carcinoma. This is also in line with data from anal cancer, which showed that induction chemotherapy may worsen local tumor control compared with chemoradiotherapy alone (23). Although the systemic failure rate was numerically lower in the induction chemotherapy group (19.1% vs 34.0%), this did not translate into a survival benefit.…”

Clinical outcome in patients treated with simultaneous integrated boost – intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal

“…This report on the use of SIB-IMRT with capecitabine and MMC for anal carcinoma shows that the efficacy is similar as in recent larger series using conventional radiation techniques [18][19][20]. This is also in accordance with a recently published smaller retrospective series, using SIB-IMRT with 5-FU instead of capecitabine [21].…”

Definitive Chemoradiotherapy for Anal Carcinoma: Long-Term Results Based on Consistent Time-to-Event Endpoints

“…In our series, the indication for colostomy was restricted to patients with persistent or recurrent disease, whereas in the literature, some trials described different cases in which a more radical approach, including colostomy, was necessary to treat CRT-related complications [5][6]17] .…”

“…Definitive chemoradiotherapy (CRT) has become the international preferred treatment, due to its clinical evidence demonstrating improved outcomes, better tolerability and considerable complete response avoiding a permanent colostomy [2][3][4] . In the last decade, different chemotherapy (CHT) regimens, as well as novel radiotherapy techniques have been tested to improve treatment efficacy and reduce morbidity [5][6][7][8][9] . Several surrogate endpoints of overall survival (OS) have been used, mainly due to the necessity of reducing trial duration and patient number.…”